Brokerages Expect Intra-Cellular Therapies Inc (NASDAQ:ITCI) Will Announce Earnings of -$0.91 Per Share

Wall Street brokerages expect Intra-Cellular Therapies Inc (NASDAQ:ITCI) to announce earnings of ($0.91) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Intra-Cellular Therapies’ earnings. The highest EPS estimate is ($0.78) and the lowest is ($1.03). Intra-Cellular Therapies posted earnings per share of ($0.75) during the same quarter last year, which would suggest a negative year-over-year growth rate of 21.3%. The firm is expected to issue its next earnings report on Wednesday, February 26th.

On average, analysts expect that Intra-Cellular Therapies will report full year earnings of ($2.85) per share for the current fiscal year, with EPS estimates ranging from ($3.10) to ($2.73). For the next financial year, analysts anticipate that the firm will report earnings of ($3.76) per share, with EPS estimates ranging from ($4.91) to ($2.44). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Intra-Cellular Therapies.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.17.

Several research firms have recently commented on ITCI. ValuEngine downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Jefferies Financial Group initiated coverage on shares of Intra-Cellular Therapies in a research note on Monday, August 12th. They set a “buy” rating and a $16.00 target price for the company. JMP Securities set a $21.00 price target on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a report on Tuesday, September 10th. BidaskClub upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Saturday, November 30th. Finally, Cantor Fitzgerald set a $27.00 price objective on shares of Intra-Cellular Therapies and gave the company a “buy” rating in a report on Tuesday, September 10th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $22.64.

In related news, EVP Mark Neumann sold 6,774 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $8.25, for a total value of $55,885.50. Following the completion of the transaction, the executive vice president now directly owns 13,448 shares of the company’s stock, valued at $110,946. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Christopher D. Alafi bought 485,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was acquired at an average cost of $10.26 per share, with a total value of $4,976,100.00. Following the completion of the acquisition, the director now owns 341,223 shares of the company’s stock, valued at approximately $3,500,947.98. The disclosure for this purchase can be found here. 18.20% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in ITCI. Quantamental Technologies LLC purchased a new position in shares of Intra-Cellular Therapies in the 2nd quarter worth approximately $49,000. Nisa Investment Advisors LLC bought a new stake in Intra-Cellular Therapies in the third quarter worth $70,000. Bank of Montreal Can lifted its position in Intra-Cellular Therapies by 114.4% in the second quarter. Bank of Montreal Can now owns 7,067 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 3,771 shares during the last quarter. First Mercantile Trust Co. boosted its stake in Intra-Cellular Therapies by 14.1% during the second quarter. First Mercantile Trust Co. now owns 13,146 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 1,624 shares during the period. Finally, Slow Capital Inc. purchased a new position in Intra-Cellular Therapies during the second quarter worth $195,000. Institutional investors and hedge funds own 71.82% of the company’s stock.

Shares of ITCI stock opened at $9.81 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.77 and a quick ratio of 7.77. Intra-Cellular Therapies has a one year low of $6.75 and a one year high of $16.76. The company’s fifty day moving average price is $9.24 and its 200-day moving average price is $10.08. The company has a market capitalization of $542.11 million, a price-to-earnings ratio of -3.45 and a beta of 1.21.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Recommended Story: Call Option

Get a free copy of the Zacks research report on Intra-Cellular Therapies (ITCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit